Literature DB >> 16997151

Pathology and molecular biology of gastric cancer.

Matti Vauhkonen1, Hanna Vauhkonen, Pentti Sipponen.   

Abstract

Several attempts to classify gastric cancer (GCA) have been made over the past decades. Most successful, and widely used, is the classification by Laurén, which distinguishes, by microscopical morphology alone, two main cancer pathogeneses, diffuse (DGCA) and intestinal (IGCA) subtypes, which appear clearly as dissimilar clinical and epidemiological entities. Here we review the main differences in epidemiology, histopathology, and molecular pathology of the two main subtypes of gastric carcinomas based on Laurén classification. In clinical practice, however, clinical staging, particularly in predicting the survival, still remains superior to all classifications of gastric cancer independent of cancer type. The existence of local precursor lesions or conditions of IGCA tumours, i.e. Helicobacter pylori gastritis, atrophic gastritis (AG), intestinal metaplasia (IM), adenoma, dysplasia, and intramucosal neoplasia, is firmly established. The links of DGCA with intestinal-type epithelium, AG or IM are poor, or do not exist. So far, H. pylori gastritis is the only universal precursor condition for DGCA. It implies that AG and achlorhydria are of minor significance and infrequent in the development of DGCA but are important steps in that of IGCA. Despite an increasing body of data, the overall view on molecular pathology of GCA remains fragmentary. No consistent differences in the molecular pathology of GCA subtypes to meet the Laurén classification have been established. With the exception of TP53, no gene mutation occurring regularly in both histological types of GCA has been reported. Chromosomal aberrations and loss of heterozygosity seem to be non-specific and do not follow any consistent route in the progression of GCA. Microsatellite instability is more commonly found in IGCA than in DGCA. The present epigenetic data suggest that most of the decrease (or loss) of gene expression may be explained by promoter hypermethylation which is more often found in IGCA. In DGCA specific genes such as CDH1 are more often hypermethylated. Compared with GCA, in premalignant condition lesions gene mutations and chromosomal aberrations are infrequent. Epigenetic dysregulation might also represent a major mechanism for altered gene expression in premalignant stages in gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997151     DOI: 10.1016/j.bpg.2006.03.016

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  54 in total

Review 1.  New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection.

Authors:  Ying-Hung Nicole Tsang; Acacia Lamb; Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

2.  Integrated analysis identified an intestinal-like and a diffuse-like gene sets that predict gastric cancer outcome.

Authors:  Cheng Zhang; Li Min; Jiafei Liu; Wei Tian; Yong Han; Like Qu; Chengchao Shou
Journal:  Tumour Biol       Date:  2016-11-17

3.  Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk.

Authors:  Hironori Masuyama; Naoto Yoshitake; Takako Sasai; Tetsuya Nakamura; Atsushi Masuyama; Toru Zuiki; Kentaro Kurashina; Mitsuyo Mieda; Keijiro Sunada; Hironori Yamamoto; Kazutomo Togashi; Akira Terano; Hideyuki Hiraishi
Journal:  Digestion       Date:  2015-01-20       Impact factor: 3.216

Review 4.  Clinical epidemiology of gastric cancer.

Authors:  Tiing Leong Ang; Kwong Ming Fock
Journal:  Singapore Med J       Date:  2014-12       Impact factor: 1.858

Review 5.  Adjuvant therapy for gastric cancer: what have we learned since INT0116?

Authors:  Alexandre A Jácome; Ajith K Sankarankutty; José Sebastião dos Santos
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

6.  A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression.

Authors:  Hyoungseok Ju; Byungho Lim; Minjin Kim; Yong Sung Kim; Woo Ho Kim; Chunhwa Ihm; Seung-Moo Noh; Dong Soo Han; Hang-Jong Yu; Bo Youl Choi; Changwon Kang
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.

Authors:  Constantinos T Giaginis; Stephanie Vgenopoulou; Gerasimos S Tsourouflis; Ekaterini N Politi; Gregorios P Kouraklis; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2008-11-06       Impact factor: 3.201

8.  The gene-reduction effect of chromosomal losses detected in gastric cancers.

Authors:  Seung-Jin Hong; Eun-Jung Jeon; Jung-Hwan Oh; Eun-Joo Seo; Sang-Wook Choi; Mun-Gan Rhyu
Journal:  BMC Gastroenterol       Date:  2010-11-20       Impact factor: 3.067

9.  Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site.

Authors:  Hongyu Wu; Jennifer A Rusiecki; Kangmin Zhu; John Potter; Susan S Devesa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

10.  Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer.

Authors:  Hiraku Itadani; Hiroko Oshima; Masanobu Oshima; Hidehito Kotani
Journal:  BMC Genomics       Date:  2009-12-17       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.